News | November 01, 2023
Mankind Pharma Q2 FY24 consolidated PAT higher at Rs. 501.02 Cr
Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023
Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023
Prateek has more than 23 years of rich experience in Human Resource
Mankind Pharma commences the commercial operations newly set-up plant in Udaipur
Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre
Cipla has a robust governance model focused on sustainability
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Subscribe To Our Newsletter & Stay Updated
